At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,473 enrolled
Drug / intervention
rizatriptan benzoate (MK0462) +1 moredrug
Likely dose
rizatriptan benzoate (MK0462) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence
In Brief
A Phase 3 clinical trial evaluating rizatriptan benzoate (MK0462) and Comparator: placebo for Migraine Headache. Completed, enrolled 1,473 participants.
Detailed Summary
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo. The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 1995
Primary CompletionJan 1996
Study CompletionJul 1996
First PostedMay 2009
TodayJul 2026
First PostedMay 12, 2009
Enrollment StartMar 1, 1995
Primary CompletionJan 1, 1996
Study CompletionJul 1, 1996
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.1 years ago
Interventions
rizatriptan benzoate (MK0462)drug
Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
Comparator: placebodrug
Placebo to rizatriptan